Osteoarthritis (OA) is the most common form of arthritis and the leading cause of disability in adults and the aging population. There is no cure for OA. ArthriC is enteric-coated capsules containing compounds identified from a generally regarded as safe pool which target a novel OA disease modifying target. Preclinical studies showed oral administration of ArthriC exerted not only disease-improvement, but also a disease-preventive (delays disease initiation), and palliative effect on OA.
Tendinopathy is a degenerative tendon disorder that affects approximately 15% athletes and 30-50% of individuals aged 60 or older. It is characterized by pain, swelling, loss of function, and impaired performance. Tendinopathy currently has no cure. Furthermore, tendinopathy often leads to tendon rupture, which is difficult to heal.
TenoGen is a biologic derived from MSCs under a specially-defined physical condition. As indicated by preclinical studies, injection of TenoGen from a patients’ own MSCs exerted efficacies on tendinopathy and ruptured tendon by turning the diseased or injured tissue into healthy tissue through regeneration.